If you're searching for a Saxenda patient assistance program because the monthly cost is standing between you and treatment, you've probably noticed the search results don't agree with each other. Some pages describe a Novo Nordisk program that hands out free Saxenda to anyone below a certain income. Others mix Saxenda up with Wegovy's savings card, which is a completely different program with completely different terms. That confusion isn't your fault — a lot of the content circulating about GLP-1 patient assistance was written for a different drug, or copied from an article about a different drug, and never corrected.
We checked Novo Nordisk's own Patient Assistance Program pages directly for this guide, on both the diabetes and obesity sides of NovoCare.com. Saxenda is not on the covered list on either side. This page explains exactly what that means, why the company has kept it that way even after a generic version arrived, and — more usefully — every real path that's still open if the cost of Saxenda or liraglutide is standing between you and your prescription.
Does Saxenda Have a Patient Assistance Program?
Novo Nordisk runs one Patient Assistance Program (PAP), and it's organized around the company's diabetes medications. The current PAP product list, published directly on NovoCare.com, covers Ozempic, Rybelsus, Victoza, and Novo Nordisk's insulin products for qualifying uninsured and Medicare patients. Saxenda does not appear on that list. Neither does Wegovy, the company's other anti-obesity medication.
This isn't a recent change. Unlike some brand drugs that get pulled from a manufacturer PAP once a generic launches, Saxenda was never added to Novo Nordisk's Patient Assistance Program in the first place, even during the years it had no generic competition at all. The company has consistently kept its weight-management drugs outside the income-based free-medication program it runs for diabetes care.
| Medication | Indication | On Novo Nordisk's PAP list (2026) |
|---|---|---|
| Saxenda (liraglutide 3 mg) | Chronic weight management | No |
| Wegovy (semaglutide) | Chronic weight management | No |
| Ozempic (semaglutide) | Type 2 diabetes | Yes, uninsured patients only, income capped at 200% FPL |
| Victoza (liraglutide 1.8 mg) | Type 2 diabetes | Yes, for qualifying uninsured and Medicare patients |
| Novo Nordisk insulins | Type 1 and type 2 diabetes | Yes, for qualifying uninsured and Medicare patients |
Watch out for sites that describe a "Saxenda Help at Hand" or "Saxenda financial assistance grant" from Novo Nordisk. Several patient-assistance directories and paid navigator sites still describe an income-based Saxenda program that, as far as we can verify on Novo Nordisk's own site, does not exist. Always confirm directly at NovoCare.com before gathering documents for an application.
Why Novo Nordisk Doesn't Cover Saxenda Under Its PAP
Manufacturer patient assistance programs are a company policy choice, not a legal requirement, and companies can draw the line around them however they choose. Novo Nordisk has chosen to route its charitable free-medication program toward chronic disease management drugs like insulin and Ozempic, where stopping treatment carries an immediate and measurable health risk. Anti-obesity medications, including Saxenda and Wegovy, have stayed on the commercial side of the business, supported by copay savings cards for insured patients rather than income-based free medication for the uninsured.
That distinction matters because it means the usual explanation for a drug disappearing from patient assistance — "a generic showed up, so the brand lost eligibility" — doesn't apply here. Teva's generic liraglutide for weight management launched in August 2025, and Saxenda's PAP status didn't change, because it was never eligible to begin with. If anything, the arrival of a generic made the practical case for adding Saxenda to a PAP weaker, not stronger, since Novo Nordisk can now point uninsured patients toward a lower-cost equivalent instead.
Why this matters for you: Don't wait for a Saxenda PAP to appear before pursuing other options. The company's obesity-medication savings pages point uninsured patients toward general strategies — comparing pharmacy prices, checking Medicaid, exploring health insurance enrollment — rather than a dedicated assistance grant. Generic liraglutide and discount cards are working solutions right now, not fallbacks while you wait.
Is There Any Way to Get Saxenda Free or Low-Cost in 2026?
Yes — just not through an income-based Novo Nordisk grant of free brand Saxenda. Here's every legitimate route still open, compared side by side.
| Option | Best For | Typical Cost |
|---|---|---|
| Generic liraglutide + discount card | Uninsured or cash-paying patients | $340–$500/month at many pharmacies (see the drug price checker) |
| Commercial insurance with prior authorization | Insured patients whose plan covers obesity drugs | Copay only, often $25–$100/month if approved |
| 340B community health centers | Patients receiving care at a qualifying clinic | Sliding scale, income-dependent |
| State Pharmaceutical Assistance Program (SPAP) | Residents of states that run one | Varies widely by state |
| Medicaid formulary coverage | Medicaid enrollees in states that cover it | Usually a small state-set copay or $0 where covered |
| Novo Nordisk Patient Assistance Program (Saxenda specifically) | No one — not currently offered for this drug | Not available |
| Novo Nordisk Saxenda Savings Card | No new enrollees — discontinued in 2023 | Not available for new patients |
If you want a full cash-price breakdown before comparing pharmacies, our drug price checker is the fastest way to see what Saxenda and generic liraglutide actually cost near you before you commit to a pharmacy.
Eligibility Comparison: Who Qualifies for What
| Program | Covers | Insurance Required? | Income-Based? |
|---|---|---|---|
| GoodRx / SingleCare discount cards | Generic liraglutide (best pricing), some brand | No — cannot combine with insurance | No |
| Commercial insurance + prior authorization | Brand or generic, plan-dependent | Commercial insurance required | No |
| State Medicaid | Generic or brand, varies by state, often with prior auth | Medicaid enrollment required | Yes |
| 340B / community health centers | Both, sliding scale | No insurance required | Yes |
| NeedyMeds / RxAssist directories | Points to whatever programs currently exist | Varies by matched program | Depends |
| Medicare Part D | Not applicable — anti-obesity drugs excluded by law | N/A | N/A |
Federal law, not company policy, is why Medicare won't help here. The Medicare Modernization Act of 2003 specifically excludes medications prescribed solely for weight loss from Part D coverage. That exclusion applies to Saxenda and generic liraglutide regardless of your income, and it isn't something Novo Nordisk or your Part D plan can override on their own. Some Medicare Advantage or Medigap plans offer limited exceptions, so it's worth checking your specific plan.
Income Limit Comparison Across Programs
Because Saxenda itself has no income-based manufacturer program, the thresholds that actually matter come from Medicaid, 340B clinics, and other Novo Nordisk medications, not from a Saxenda-specific rule. Here's how they compare using the 2026 Federal Poverty Level of $33,000 for a family of four in the 48 contiguous states, published by HHS in January 2026.
| Program | Income Threshold | Approx. Annual Income (Family of 4) |
|---|---|---|
| Medicaid (varies by state) | Often 138%–200% FPL for adults | ~$45,540–$66,000 |
| 340B sliding-scale clinics | Clinic-specific, often up to 200% FPL for the deepest discount | Up to ~$66,000 |
| Novo Nordisk PAP — Ozempic (uninsured) | Up to 200% FPL | Up to ~$66,000 |
| Novo Nordisk PAP — Victoza and insulins (uninsured) | Up to 400% FPL | Up to ~$132,000 |
| Novo Nordisk PAP — Saxenda | Not applicable | No program exists |
That last row is the one worth sitting with. Novo Nordisk's own diabetes medications use income ceilings as generous as 400% of the poverty level. Saxenda isn't held to a stricter income rule — it simply isn't part of the income-based program at all, which is a different and more limiting problem than a tight eligibility cutoff would be.
Covered Medications: Brand vs. Generic Support
| Medication | Manufacturer PAP | Manufacturer Copay Card | Discount Card Pricing | Medicare/Medicaid |
|---|---|---|---|---|
| Brand Saxenda (Novo Nordisk) | Not offered | Discontinued for new enrollees since 2023 | Available, usually higher than generic | Medicaid varies by state; Medicare excluded by law |
| Generic liraglutide 3 mg (Teva) | Generics rarely have manufacturer PAPs | Not applicable to generics | Yes — typically the lowest price | Same Medicaid/Medicare rules as brand |
| Wegovy (semaglutide, Novo Nordisk) | Not offered | Active — as low as $25/month for commercially insured patients | NovoCare Pharmacy self-pay available | Medicare excluded for weight loss; limited CV-risk coverage |
| Zepbound (tirzepatide, Eli Lilly) | Not currently offered by Lilly Cares | Active — as low as $25/month for commercially insured patients | LillyDirect self-pay available | Medicare excluded for weight loss |
The pattern across anti-obesity GLP-1s is consistent: manufacturer copay cards exist for the insured, but none of the three major brands currently run an income-based free-medication program for uninsured weight-management patients the way they do for their diabetes drugs.
Step-by-Step: How to Get Help Paying for Saxenda or Generic Liraglutide
Ask your prescriber about generic liraglutide
Teva's generic liraglutide 3 mg is FDA-approved as therapeutically equivalent to brand Saxenda for weight management. Unless there's a specific clinical reason to stay on brand, switching is usually the single biggest cost reduction available to you.
Price the generic with a free discount card before you fill
Compare cash prices using GoodRx or SingleCare at two or three nearby pharmacies before assuming the price you saw online is what you'll pay locally. Our GoodRx vs. Inside Rx comparison walks through how to check both.
If you're commercially insured, check your formulary and ask about prior authorization
Anti-obesity coverage varies a lot by employer plan. If your plan requires prior authorization, your prescriber's office will need to submit documentation showing you meet the BMI and comorbidity criteria in Saxenda's FDA labeling.
If you're on Medicaid, confirm your state's specific rules
Some states cover Saxenda or generic liraglutide for qualifying patients with prior authorization; many don't cover anti-obesity medications at all. Check your state Medicaid formulary directly or ask your pharmacist to run a test claim before assuming either way.
If you're uninsured and still can't afford it, search independent directories
NeedyMeds and RxAssist maintain searchable databases of state programs, charitable funds, and discount cards that change over time. They won't manufacture a Saxenda-specific PAP that doesn't exist, but they may surface a state or nonprofit option you haven't tried.
Ask about a 340B clinic near you
Federally Qualified Health Centers and other 340B-participating providers often offer sliding-scale pricing on both brand and generic medications based on household income, independent of any manufacturer program.
Decision Tree: What Should You Do Right Now?
Do you currently have insurance that covers weight-management drugs?
This determines which savings path actually applies to you
Confirm your copay tier
Ask your plan whether brand Saxenda or generic liraglutide sits on a lower tier
If your plan excludes obesity drugs
Ask your prescriber about a formulary exception or appeal before paying cash
Ask about generic liraglutide first
Price it with GoodRx or SingleCare before considering brand Saxenda
Still unaffordable
Check a 340B clinic, your state Medicaid rules, or a state pharmaceutical assistance program
Still can't afford it?
Talk to your prescriber about whether Wegovy or Zepbound — both of which have active manufacturer savings cards — could be a clinically appropriate alternative
Application Process for Each Option
| Program | How to Apply |
|---|---|
| GoodRx / SingleCare | Free sign-up online or via app; present the coupon or card at the pharmacy counter |
| Commercial insurance prior authorization | Your prescriber's office submits a PA request with documentation of BMI and weight-related comorbidities |
| Medicaid | Apply through your state Medicaid agency or Healthcare.gov if you're not yet enrolled |
| 340B community health center | Schedule an appointment at a qualifying clinic and ask about their sliding-fee scale |
| NeedyMeds / RxAssist | Search by drug name on their websites; each matched program has its own application |
Never pay an upfront fee to "apply" for a manufacturer savings card or PAP. Legitimate manufacturer programs are free to enroll in directly through the company's own site. If a third-party service asks for payment before connecting you to a program, treat that as a red flag.
Approval and Processing Timelines
| Program | Typical Timeline |
|---|---|
| Discount cards (GoodRx, SingleCare) | Instant; no waiting period |
| Commercial insurance prior authorization | Typically 3–14 business days, depending on the plan |
| Medicaid enrollment | Varies by state; often 15–45 days for a full application |
| 340B clinic sliding-scale approval | Often same-visit once income documentation is reviewed |
Renewing or Reapplying for Assistance
- Prior authorization approvals for commercial insurance are usually tied to your plan year and may need to be resubmitted annually or when you switch plans.
- Medicaid requires periodic redetermination, typically annually, to confirm continued eligibility.
- Discount cards like GoodRx don't expire or require renewal — the price simply updates automatically.
- 340B clinic sliding-scale pricing is usually reassessed each time your income documentation is refreshed, often annually.
- Since Novo Nordisk's PAP product list can change at any time, it's worth rechecking directly at NovoCare.com every year or so in case Saxenda's status shifts.
Pros and Cons of Each Path
Pros
- Generic liraglutide with a discount card is dramatically cheaper than brand Saxenda's cash price, often by $800 or more per month
- 340B clinics and state Medicaid programs exist independent of anything Novo Nordisk decides to do with Saxenda
- Discount cards can be combined with pharmacy-specific savings clubs for even lower prices
- Talking to your prescriber about Wegovy or Zepbound opens up active manufacturer copay cards if a switch is clinically appropriate
Cons
- Uninsured patients who specifically need brand Saxenda have no free option through Novo Nordisk, and likely never will based on the company's current program structure
- Medicare beneficiaries are excluded from Part D coverage by federal law, not just company policy, so there's no workaround based on income alone
- Medicaid coverage is inconsistent state to state, so patients can't assume coverage without checking directly
- Some third-party "assistance finder" services charge fees for matching you to programs you could apply to yourself for free
Common Mistakes That Cost Patients Money
- Assuming an older article's description of a "Saxenda patient assistance program" is accurate, when it may be describing Wegovy, Ozempic, or a program that never existed.
- Trying to use a Saxenda savings card in 2026 — the program was discontinued for new enrollees in 2023 and no longer works at the pharmacy counter.
- Paying full brand-name cash price without ever pricing generic liraglutide with a free discount card first.
- Assuming your insurance automatically covers weight-management drugs the same way it covers other prescriptions — many plans exclude the category entirely.
- Giving payment information to a "patient assistance" service before confirming the underlying program actually exists and is free to apply to directly.
- Confusing Saxenda's liraglutide with Victoza's liraglutide — they're the same active ingredient at different doses, but only Victoza is eligible for Novo Nordisk's PAP.
Real Examples: How Patients Are Handling This
Example 1 — Uninsured adult, previously on brand: A patient who assumed Novo Nordisk would offer income-based assistance for Saxenda the way it does for Ozempic finds no such program exists. Their prescriber switches them to generic liraglutide, and a SingleCare coupon brings the monthly cost down to roughly $400 — still a real expense, but a fraction of brand Saxenda's list price.
Example 2 — Commercially insured, plan requires prior authorization: A patient whose employer plan covers anti-obesity medications with documentation submits BMI and comorbidity records through their prescriber. Once approved, their copay drops to a manageable tier, since no manufacturer card is needed when insurance itself covers the claim.
Example 3 — Medicaid enrollee checking state rules first: A patient on Medicaid in a state that covers liraglutide for qualifying adults confirms coverage directly with their state's Medicaid formulary before filling, rather than assuming coverage exists — and avoids an unexpected full-price bill at the pharmacy.
Saxenda vs. Other GLP-1 Assistance Programs
It's worth zooming out, because Saxenda's situation isn't unique — it reflects how manufacturers have structured assistance differently across the GLP-1 category depending on the drug's indication.
| Medication | Indication | Manufacturer PAP Status |
|---|---|---|
| Saxenda (liraglutide, Novo Nordisk) | Weight management | Not offered |
| Wegovy (semaglutide, Novo Nordisk) | Weight management | Not offered |
| Zepbound (tirzepatide, Eli Lilly) | Weight management | Not currently offered by Lilly Cares |
| Ozempic (semaglutide, Novo Nordisk) | Type 2 diabetes | Yes, via Novo Nordisk PAP, uninsured patients |
| Mounjaro (tirzepatide, Eli Lilly) | Type 2 diabetes | Yes, via Lilly Cares Foundation |
If your household relies on more than one GLP-1 prescription, don't assume the assistance rules for one drug apply to another, even from the same manufacturer. Check that specific drug's current eligibility page directly, the same way we did for this guide, since a diabetes indication and a weight-management indication from the same company can land on completely different sides of the PAP line.
Bottom Line
Saxenda has never had a manufacturer income-based patient assistance program, and its savings card for insured patients has been gone since 2023. That's a genuinely tougher starting position than some other brand medications, but it isn't a dead end. Generic liraglutide with a free discount card typically costs a fraction of brand Saxenda's price, Medicaid coverage is worth checking directly by state, and 340B clinics remain open regardless of what Novo Nordisk does with its assistance program.
The fastest way to lower your cost is usually the simplest: confirm with your prescriber whether generic liraglutide is appropriate for you, price it against your insurance copay or cash cost with a discount card, and only pursue brand-specific coverage appeals if there's a genuine clinical reason to stay on brand Saxenda.